{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:54:44Z","timestamp":1794563684909,"version":"4.9.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"62","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA199338"],"award-info":[{"award-number":["U01CA199338"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA253915"],"award-info":[{"award-number":["U01CA253915"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["L60CA274879"],"award-info":[{"award-number":["L60CA274879"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA97186"],"award-info":[{"award-number":["P50CA97186"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA221836"],"award-info":[{"award-number":["R50CA221836"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Damon Runyon Cancer Research Foundation and the Bristol Myers Squibb Foundation","id":[{"id":"https:\/\/ror.org\/01gd7b947","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Andy Hill Cancer Research Endowment (CARE) Fund","award":["2021-DR-01"],"award-info":[{"award-number":["2021-DR-01"]}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110531"],"award-info":[{"award-number":["W81XWH2110531"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To investigate the relative contributions of natural history and clinical interventions to racial disparities in prostate cancer mortality in the United States, we extended a model that was previously calibrated to Surveillance, Epidemiology, and End Results (SEER) incidence rates for the general population and for Black men. The extended model integrated SEER data on curative treatment frequencies and cancer-specific survival. Starting with the model for all men, we replaced up to 9 components with corresponding components for Black men, projecting age-standardized mortality rates for ages 40-84\u2009years at each step. Based on projections in 2019, the increased frequency of developing disease, more aggressive tumor features, and worse cancer-specific survival in Black men diagnosed at local-regional and distant stages explained 38%, 34%, 22%, and 8% of the modeled disparity in mortality. Our results point to intensified screening and improved care in Black men as priority areas to achieve greater equity.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgad018","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:25:19Z","timestamp":1689179119000},"page":"212-218","source":"Crossref","is-referenced-by-count":20,"title":["Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors"],"prefix":"10.1093","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-6567","authenticated-orcid":false,"given":"Roman","family":"Gulati","sequence":"first","affiliation":[{"name":"Division of Public Health Sciences, Biostatistics Program, Fred Hutchinson Cancer Center , Seattle, WA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-6749","authenticated-orcid":false,"given":"Yaw A","family":"Nyame","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Biostatistics Program, Fred Hutchinson Cancer Center , Seattle, WA,","place":["USA"]},{"name":"Department of Urology, University of Washington Medical Center , Seattle, WA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M","family":"Lange","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Biostatistics Program, Fred Hutchinson Cancer Center , Seattle, WA,","place":["USA"]},{"name":"Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University , Portland, OR,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-9986","authenticated-orcid":false,"given":"Jonathan E","family":"Shoag","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH,","place":["USA"]},{"name":"Department of Urology, Weill Cornell Medicine , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-2879","authenticated-orcid":false,"given":"Alex","family":"Tsodikov","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan , Ann Arbor, MI,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-6370","authenticated-orcid":false,"given":"Ruth","family":"Etzioni","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Biostatistics Program, Fred Hutchinson Cancer Center , Seattle, WA,","place":["USA"]},{"name":"Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University , Portland, OR,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2024110801012053000_lgad018-B1","author":"Surveillance Epidemiology and End Results (SEER) Program","year":"2022"},{"issue":"3","key":"2024110801012053000_lgad018-B2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.eururo.2020.09.002","article-title":"Findings from a genetic sequencing investigation of men with familial and aggressive prostate cancer","volume":"79","author":"Darst","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"2024110801012053000_lgad018-B3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2021.12.023","article-title":"A rare germline HOXB13 variant contributes to risk of prostate cancer in men of African ancestry","volume":"81","author":"Darst","year":"2022","journal-title":"Eur Urol"},{"issue":"9","key":"2024110801012053000_lgad018-B4","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/0008-5472.CAN-17-1550","article-title":"Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent","volume":"78","author":"Lachance","year":"2018","journal-title":"Cancer Res"},{"issue":"9","key":"2024110801012053000_lgad018-B5","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2105\/AJPH.2006.102525","article-title":"Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities","volume":"98","author":"Warnecke","year":"2008","journal-title":"Am J Public Health"},{"issue":"5","key":"2024110801012053000_lgad018-B6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2016.08.047","article-title":"Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer","volume":"71","author":"Gray","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"2024110801012053000_lgad018-B7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/pcan.2017.35","article-title":"Contemporary management of men with high-risk localized prostate cancer in the United States","volume":"20","author":"Weiner","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"2024110801012053000_lgad018-B8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.juro.2018.10.024","article-title":"Quality of care in the treatment of localized intermediate and high risk prostate cancer at minority serving hospitals","volume":"201","author":"Krimphove","year":"2019","journal-title":"J Urol"},{"issue":"5","key":"2024110801012053000_lgad018-B9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.18.01279","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024110801012053000_lgad018-B10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euo.2021.07.006","article-title":"Prostate cancer racial disparities: a systematic review by the Prostate Cancer Foundation Panel","volume":"5","author":"Mahal","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"2024110801012053000_lgad018-B11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"2024110801012053000_lgad018-B12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/cncr.33419","article-title":"Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy","volume":"127","author":"Wilkins","year":"2021","journal-title":"Cancer"},{"issue":"6","key":"2024110801012053000_lgad018-B13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/jnci\/djaa172","article-title":"Prostate cancer screening guidelines for Black men: spotlight on an empty stage","volume":"113","author":"Etzioni","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2024110801012053000_lgad018-B14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2022.03.007","article-title":"Deconstructing, addressing, and eliminating racial and ethnic inequities in prostate cancer care","volume":"82","author":"Nyame","year":"2022","journal-title":"Eur Urol"},{"issue":"12","key":"2024110801012053000_lgad018-B15","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/cncr.30687","article-title":"Is prostate cancer different in Black men? Answers from 3 natural history models","volume":"123","author":"Tsodikov","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"2024110801012053000_lgad018-B16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/biostatistics\/kxq036","article-title":"Calibrating disease progression models using population data: a critical precursor to policy development in cancer control","volume":"11","author":"Gulati","year":"2010","journal-title":"Biostatistics"},{"issue":"3","key":"2024110801012053000_lgad018-B17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Ann Intern Med"},{"issue":"9","key":"2024110801012053000_lgad018-B18","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.22607","article-title":"Reconstructing PSA testing patterns between Black and White men in the US from Medicare claims and the National Health Interview Survey","volume":"109","author":"Mariotto","year":"2007","journal-title":"Cancer"},{"issue":"19","key":"2024110801012053000_lgad018-B19","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jnci\/djm153","article-title":"Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence","volume":"99","author":"Haas","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2024110801012053000_lgad018-B20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1055-9965.EPI-10-0718","article-title":"What if I don\u2019t treat my PSA-detected prostate cancer? Answers from three natural history models","volume":"20","author":"Gulati","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"22","key":"2024110801012053000_lgad018-B21","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1002\/cncr.28932","article-title":"Expected population impacts of discontinued prostate-specific antigen screening","volume":"120","author":"Gulati","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"2024110801012053000_lgad018-B22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2018.08.032","article-title":"Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in Black men","volume":"75","author":"Preston","year":"2019","journal-title":"Eur Urol"},{"issue":"36","key":"2024110801012053000_lgad018-B23","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1200\/JCO.2016.68.1965","article-title":"Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: results from two large randomized clinical trials","volume":"34","author":"Tangen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024110801012053000_lgad018-B24","doi-asserted-by":"crossref","first-page":"evidoa2200031","DOI":"10.1056\/EVIDoa2200031","article-title":"Harm-to-benefit of three decades of prostate cancer screening in Black men","volume":"1","author":"Basourakos","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"2024110801012053000_lgad018-B25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djaa171","article-title":"Racial and ethnic variation in PSA testing and prostate cancer incidence following the 2012 USPSTF recommendation","volume":"113","author":"Kensler","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"2024110801012053000_lgad018-B26","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1002\/cncr.27594","article-title":"The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines","volume":"118","author":"Etzioni","year":"2012","journal-title":"Cancer"},{"issue":"10","key":"2024110801012053000_lgad018-B27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jnci\/djaa001","article-title":"Lifetime benefits and harms of prostate-specific antigen-based risk-stratified screening for prostate cancer","volume":"112","author":"Heijnsdijk","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2024110801012053000_lgad018-B28","doi-asserted-by":"crossref","first-page":"e221116","DOI":"10.1001\/jamahealthforum.2022.1116","article-title":"Evaluation of prostate cancer screening strategies in a low-resource, high-risk population in the Bahamas","volume":"3","author":"Heijnsdijk","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"24","key":"2024110801012053000_lgad018-B29","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer \u2013 29-year follow-up","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2024110801012053000_lgad018-B30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cncr.31178","article-title":"The efficacy of PSA screening: impact of key components in the ERSPC and PLCO trials","volume":"124","author":"De Koning","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"2024110801012053000_lgad018-B31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"2024110801012053000_lgad018-B32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2307\/2347496","article-title":"A method for computing profile-likelihood-based confidence intervals","volume":"37","author":"Venzon","year":"1988","journal-title":"Appl Stat"},{"issue":"12","key":"2024110801012053000_lgad018-B33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/0895-4356(94)90089-2","article-title":"A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer","volume":"47","author":"Chu","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2024110801012053000_lgad018-B34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jnci\/91.12.1025","article-title":"Cancer surveillance series: interpreting trends in prostate cancer\u2013Part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality","volume":"91","author":"Feuer","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2024110801012053000_lgad018-B35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00001648-199703000-00001","article-title":"Prostate cancer incidence and mortality rates among White and Black men","volume":"8","author":"Merrill","year":"1997","journal-title":"Epidemiology"},{"issue":"21","key":"2024110801012053000_lgad018-B36","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in Black men with prostate cancer: a literature review","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"issue":"8","key":"2024110801012053000_lgad018-B37","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/cncr.31253","article-title":"Racial disparities in prostate cancer survival in a screened population: reality versus artifact","volume":"124","author":"Kaur","year":"2018","journal-title":"Cancer"},{"issue":"25","key":"2024110801012053000_lgad018-B38","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMsb2000250","article-title":"Reconsidering the trade-offs of prostate cancer screening","volume":"382","author":"Shoag","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2024110801012053000_lgad018-B39","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/djab072","article-title":"The impact of intensifying prostate cancer screening in Black men: a model-based analysis","volume":"113","author":"Nyame","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"2024110801012053000_lgad018-B40","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1001\/jama.2018.11716","article-title":"Prostate cancer-specific mortality across Gleason scores in Black vs nonblack men","volume":"320","author":"Mahal","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"2024110801012053000_lgad018-B41","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1200\/j.clin.oncol.22.02203:JCO2202203","article-title":"Racism does not cause prostate cancer, it causes prostate cancer death","volume":"41","author":"Vickers","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2023\/62\/212\/53862466\/lgad018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2023\/62\/212\/53862466\/lgad018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T20:02:46Z","timestamp":1731009766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2023\/62\/212\/7342429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":41,"journal-issue":{"issue":"62","published-online":{"date-parts":[[2023,11,8]]},"published-print":{"date-parts":[[2023,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgad018","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,11,1]]}}}